RecruitingEarly Phase 1NCT06613841

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Abramson Cancer Center at Penn Medicine
Principal Investigator
Ali Nabavizadeh, MD, MD
University of Pensylvania
Intervention
Fluciclovine F18(drug)
Enrollment
15 target
Eligibility
18 years · All sexes
Timeline
2025 – 2026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06613841 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma →

← Back to all trials